Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Regencell Bioscience Holdings Ltd
NASDAQ RGC
Data sourced from
and
and
Regencell Bioscience Holdings Ltd Gross Profit for the quarter ending September 30, 2023: USD -769.69 K
Regencell Bioscience Holdings Ltd Gross Profit is USD -769.69 K for the quarter ending September 30, 2023. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
-
Regencell Bioscience Holdings Ltd Gross Profit for the quarter ending March 31, 2017 was USD 507.30 M.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: RGC
| CEO | Mr. Yat-Gai Au |
| IPO Date | July 16, 2021 |
| Location | Hong Kong |
| Headquarters | First Commercial Building, Causeway Bay, Hong Kong |
| Employees | 12 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Key trends
Similar companies
Eagle Pharmaceuticals Inc
NA
NA
Phibro Animal Health Corporation
NA
NA
Procaps Group SA
NA
NA
StockViz Staff
September 16, 2024
Any question? Send us an email